Pharvaris N.V. (NASDAQ: PHVS) announced that two articles detailing Phase 2 clinical study results for its drug deucrictibant have been published in The Lancet Haematology. The studies, CHAPTER-1 and RAPIDe-1, evaluated the drug for preventing and treating hereditary angioedema attacks.

The CHAPTER-1 study tested deucrictibant as a preventive treatment for hereditary angioedema attacks. Results showed a statistically significant reduction in attack occurrence and improvements in disease control and health-related quality of life compared to placebo. The drug was well tolerated at both tested doses.

The RAPIDe-1 study examined deucrictibant immediate-release capsules for on-demand treatment of attacks. The study demonstrated statistically significant reduction in attack severity, reduced time to symptom relief and resolution compared to placebo. All tested doses were well tolerated.

Deucrictibant is an oral bradykinin B2 receptor antagonist being developed in two formulations: an extended-release tablet for prevention and an immediate-release capsule for acute treatment. The drug has received orphan drug designation from the U.S. Food and Drug Administration, European Commission, and Swissmedic.

The company expects topline data from its Phase 3 CHAPTER-3 study evaluating the extended-release tablet for prevention in the third quarter of 2026. Pharvaris plans to submit a New Drug Application to the FDA in the first half of 2026 for the on-demand treatment indication.

Pharvaris is a late-stage biopharmaceutical company focused on developing oral treatments for bradykinin-mediated diseases including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency.